Category: News

21. December 2017

Brussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau

The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.

11. July 2017

Endomedica GmbH, our wholly owned subsidiary based in Halle, was able to present itself to a wide audience including well-known pharmaceutical companies and investors from the fields of biotechnology and medical technology at the Health Innovation Summit on 11.7.2017.

The event took place simultaneously as a webinar in Munich, Tokyo and Silicon Valley and allowed discussion rounds after the presentation.

22. June 2017

On 22 June 2017, the AMW received a high visit from the Bavarian Minister of Economic Affairs and Deputy Prime Minister of the Free State of Bavaria.

Within this framework, the pharmaceutical plant was able to present itself as the largest training company in Warngau.

9. November 2016

Specialty pharmaceutical company AMW takes big steps

Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialist pharmaceutical company with bright prospects. The company develops and distributes transdermal systems, i.e. active ingredients that enter the body through the skin, as well as implants loaded with highly effective active ingredients, which release their active ingredient evenly to the body for months and dissolve completely. AMW is supported by well-known investors. In a recent financing round to finance growth, investors reaffirmed their commitment to AMW and contributed a further six million euros.

6. February 2016

Chamber of Commerce Munich and Upper Bavaria: Training company 2016

This company ensures qualitythrough vocational training in several occupations.

4. November 2015

For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.

The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.